Who Supplies Warfarin to India from UNITED KINGDOM

The importation of finished pharmaceutical formulations into India is regulated under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. To import such formulations, the foreign manufacturer must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application process involves submitting detailed product information, manufacturing licenses, and compliance with Good Manufacturing Practices (GMP). The registration process typically takes several months, depending on the completeness of the application and the CDSCO's evaluation. For formulations containing Warfarin under HS Code 30049099, specific documentation, including a Certificate of Pharmaceutical Product (CoPP), stability data, and a No Objection Certificate (NOC) from the manufacturer, is required. The timeline for import drug registration can vary but generally spans 6 to 12 months.

Upon arrival in India, imported pharmaceutical formulations must undergo quality testing to ensure compliance with Indian standards. This includes batch-wise testing by CDSCO-approved laboratories, where each batch is tested for identity, purity, strength, and quality. A Certificate of Analysis (CoA) from the manufacturer, along with stability data (preferably in ICH Zone IV conditions), is mandatory. The formulations must conform to the standards set by the Indian Pharmacopoeia. Port inspections by customs drug inspectors are conducted to verify compliance, and any discrepancies can lead to delays or rejection of the shipment.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for the import of pharmaceutical formulations, emphasizing enhanced quality control and compliance with international standards. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially affecting the volume of imported formulations. Bilateral agreements between India and the United Kingdom have facilitated smoother trade relations, with mutual recognition of GMP certifications and streamlined approval processes.

India imports finished Warfarin formulations primarily due to the demand for patented or branded products, specialized dosage forms, and formulations not manufactured domestically. The domestic capacity for Warfarin formulations is limited, leading to a reliance on imports to meet therapeutic needs. The market size for Warfarin formulations in India is substantial, with a growing patient population requiring anticoagulant therapy.

The import duty structure for Warfarin formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%, a Social Welfare Surcharge (SWS) of 10% on BCD, and an Integrated Goods and Services Tax (IGST) of 12%. There are no additional cesses applicable. Exemptions may apply under specific Free Trade Agreements (FTAs), but as of the latest available data, no preferential tariff rates are specified for imports from the United Kingdom. The total landed duty percentage is approximately 23.536%.

India sources Warfarin formulations from the United Kingdom due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. The United Kingdom's pharmaceutical industry is known for its stringent quality controls and adherence to international standards, making it a preferred supplier. Other suppliers, such as China, Germany, and the United States, also export Warfarin formulations to India; however, the United Kingdom's reputation for quality and reliability provides a competitive advantage. The United Kingdom holds a significant share in India's Warfarin import market, contributing to the diversity and quality of available formulations.

India imports Warfarin formulations from the United Kingdom due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. The United Kingdom's pharmaceutical industry is known for its stringent quality controls and adherence to international standards, making it a preferred supplier. Specific formulations, such as extended-release tablets or combination therapies, may not be manufactured domestically, necessitating imports to meet patient needs.

When compared to other origins like China, Germany, and the United States, the United Kingdom offers competitive advantages in terms of quality, regulatory compliance, and reliability. While China may offer lower prices, concerns about quality and regulatory standards can be a deterrent. Germany and the United States also provide high-quality formulations but may have higher costs. The United Kingdom's balance of quality and cost-effectiveness positions it favorably in the Indian market.

Indian importers face several supply chain risks, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have occurred due to manufacturing issues or logistical challenges. To mitigate these risks, importers should diversify their supplier base, monitor currency trends, stay updated on regulatory changes, and maintain robust quality assurance processes.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP) to manage financial risk.
4. 4Minimum Order Quantities (MOQs): Align order quantities with market demand to optimize inventory costs.
5. 5Supplier Qualification: Conduct thorough due diligence on suppliers, including audits and assessments of their manufacturing facilities and quality control processes.